secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001628280-26-017046
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.01, 7.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar sells Sec61 assets (incl. KZR-261) to Enodia for $1M upfront, up to $127M milestones
--------------------------------------------------------------------------------

- Kezar receives $1M cash upfront ($800K at close, $200K later) for its Sec61-based discovery program and KZR-261.
- Eligible for up to $127M in development, regulatory and commercial milestone payments plus tiered royalties on net sales.
- Kezar retains its zetomizomib program; no other assets (cash, equipment, employee contracts) transferred.
- Transaction closed March 6, 2026; joint press release issued March 12, 2026.
- Agreement includes indemnification caps of $1M per party (excluding fraud) and customary covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000162828026017046/0001628280-26-017046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000162828026017046/kzr-20260306.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-017046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer